Heparin Market

Overview

The global Heparin Market was valued at USD 7.61 billion in 2025 and is projected to reach USD 11.70 billion by 2034, growing at a CAGR of 4.9% during the forecast period (2026–2034). The market is driven by the rising prevalence of cardiovascular diseases, increasing surgical procedures, and growing demand for anticoagulant therapies. The market is shifting from a near-total reliance on porcine-sourced crude heparin toward a more diversified raw-material base, as recurring African Swine Fever outbreaks in China have repeatedly threatened global supply continuity. Manufacturers are investing in bovine-sourced heparin re-qualification, and a small but growing group of biotechnology companies is advancing synthetic and biosynthetic heparin produced via cell and enzyme engineering platforms that bypass animal-derived raw materials entirely. Established pharmaceutical manufacturers are simultaneously expanding premixed and ready-to-administer heparin injection formats to improve bedside safety and address recurring product-specific shortages. Government initiatives are reinforcing this diversification. In the United States, the Food and Drug Administration has encouraged heparin manufacturers to develop good manufacturing practices for bovine-sourced heparin, supporting an alternative raw-material pathway as renewed swine disease outbreaks in China continue to strain porcine-derived supply. The U.S. Department of Commerce has also launched a Section 232 national-security investigation into pharmaceutical import dependency, prompting industry comments on the country’s reliance on Chinese-sourced heparin raw material. In the United Kingdom, NHS England has issued a national procurement notice for low molecular weight heparin supply, with contracts worth an estimated USD 90 million running from 2026 through 2028. By region, North America held the largest share of the market in 2025, supported by high rates of cardiovascular intervention, established hospital procurement infrastructure, and strong presence of major branded heparin manufacturers. Asia-Pacific is expected to grow at the fastest CAGR during the forecast period, driven by rising surgical volumes, expanding dialysis infrastructure, and continued growth of China-based API manufacturing capacity serving both domestic and export markets.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Diversification Toward Bovine and Biosynthetic Heparin Sourcing Emerging as a Transformational Trend

• Manufacturers and regulators are actively re-qualifying bovine-sourced heparin as an alternative raw-material pathway, supported by improved purification techniques that address historical bovine spongiform encephalopathy concerns.
• A small group of biotechnology companies is advancing synthetic and biosynthetic heparin using cell and enzyme engineering platforms, aiming to replicate the anticoagulant activity of pharmaceutical heparin without reliance on animal-derived raw material.
• Established manufacturers are expanding premixed, ready-to-administer heparin injection formats to improve bedside dosing safety and reduce the operational impact of recurring product-specific shortages on hospital pharmacies.
• The US FDA encouraged heparin manufacturers to develop good manufacturing practices for bovine-sourced heparin, formally supporting supply diversification beyond the porcine-dominated raw-material base.

KEY MARKET DRIVER

Rising Global Burden of Cardiovascular and Thromboembolic Disease is the Key Driver

• Cardiovascular diseases remain among the leading global causes of death, with thromboembolic conditions such as deep vein thrombosis and pulmonary embolism accounting for a significant share of anticoagulation therapy demand worldwide.
• Rising surgical procedure volumes, including cardiac catheterization, coronary artery bypass grafting, angioplasty, and vascular surgery, continue to drive sustained perioperative heparin demand across hospital settings.
• Expanding use of heparin in extracorporeal membrane oxygenation and cardiopulmonary bypass circuits is broadening the clinical base for intravenous heparin administration beyond traditional surgical prophylaxis.
• The US Department of Commerce opened a Section 232 national-security investigation into pharmaceutical import dependency via a Federal Register notice, drawing industry comment, including from biosynthetic heparin developer TEGA Therapeutics, on US reliance on Chinese porcine-sourced heparin raw material.

KEY MARKET OPPORTUNITY

Expansion of Non-Porcine Heparin Manufacturing Capacity Creates Significant Opportunity

• Growing regulatory and institutional support for bovine-sourced and biosynthetic heparin is creating commercial opportunities for manufacturers willing to invest in alternative raw-material qualification ahead of competitors still reliant solely on porcine supply.
• Rising dialysis and oncology procedure volumes in emerging markets are expanding demand for both branded and generic low molecular weight heparin products, particularly in outpatient and homecare settings.
• Government procurement programs, such as NHS England's national low molecular weight heparin supply contracts, are providing manufacturers with multi-year demand visibility that supports capacity-investment decisions.
• NHS England published a national procurement notice for low molecular weight heparin supply across multiple English regions, with an estimated contract value of USD 90 million running from 2026 to 2028 and extendable to 2030.

Global Heparin Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product Type

Low molecular weight heparin (LMWH) held the largest market position in 2025, supported by its predictable pharmacokinetics, convenient once-daily dosing, reduced monitoring requirements, and favorable safety and efficacy profile compared with unfractionated heparin. These advantages have increased its adoption across surgical prophylaxis, oncology-related anticoagulation, pregnancy-associated thrombosis management, and outpatient treatment settings, where convenient administration and consistent anticoagulant effects are important.

Synthetic and biosynthetic heparin is projected to grow at the fastest CAGR during the forecast period, driven by continued investment in chemo-enzymatic and fermentation-based production technologies that can reduce dependence on porcine-derived raw materials, improve supply-chain resilience, and enable more controlled and scalable manufacturing. Growing regulatory and institutional interest in diversifying heparin supply sources, particularly following recurring African Swine Fever-related disruptions and shortages, is further encouraging research, commercial development, and adoption of alternative production pathways.

Product Type categories include

• Low Molecular Weight Heparin (Dominating Segment)
• Synthetic & Biosynthetic Heparin (Highest CAGR Segment)
• Unfractionated Heparin
• Ultra-Low Molecular Weight Heparin

Analysis by Source

Porcine-sourced heparin held the largest market position in 2025, supported by its established use as the primary raw-material source, mature processing infrastructure, extensive supplier networks, and well-developed API supply chains. Its long history of commercial production and broad acceptance among pharmaceutical manufacturers continue to support its leading position in the market. The availability of established extraction and purification capabilities further strengthens its role across pharmaceutical manufacturing.

Bovine-sourced heparin is projected to grow at the fastest CAGR during the forecast period, driven by increasing regulatory encouragement, efforts to diversify raw-material sources, and growing demand for more resilient supply chains. Recurring disruptions to porcine-derived heparin supplies are also encouraging manufacturers to explore bovine alternatives and invest in reliable sourcing and production capabilities. Expanding validation and manufacturing capabilities are expected to further improve the commercial viability of bovine-sourced heparin.

Source categories include

• Porcine (Dominating Segment)
• Bovine (Highest CAGR Segment)

Analysis by Route of Administration

Subcutaneous administration held the largest market position in 2025, supported by its suitability for outpatient and homecare anticoagulation therapy, particularly for low molecular weight heparin formulations that offer predictable anticoagulant effects without continuous intravenous monitoring. Its ease of administration and reduced dependence on hospital-based care further support widespread use across thrombosis prevention and treatment.

Intravenous administration is projected to grow at the fastest CAGR during the forecast period, driven by expanding use of heparin in extracorporeal membrane oxygenation, cardiopulmonary bypass, and other perioperative settings that require rapid-onset and closely monitored anticoagulation. Its ability to provide immediate and adjustable anticoagulant effects makes it particularly valuable in complex hospital and critical-care procedures.

Route of Administration categories include

• Subcutaneous (Dominating Segment)
• Intravenous (Highest CAGR Segment)

Analysis by Application

Cardiovascular disease treatment held the largest market position in 2025, supported by the high global prevalence of thromboembolic conditions and the established role of heparin in acute and preventive cardiovascular care. Its rapid anticoagulant action and broad clinical use across hospital and post-operative settings continue to sustain demand for thrombosis prevention and treatment. Growing rates of cardiovascular procedures and hospitalization for thrombotic complications further support the segment’s continued importance.

Oncology is projected to grow at the fastest CAGR during the forecast period, driven by the elevated risk of cancer-associated thrombosis among oncology patients and increasing clinical use of low molecular weight heparin for anticoagulation management during cancer treatment. Growing recognition of thrombosis as a significant complication of cancer and its therapies is further supporting demand for effective anticoagulant treatment. Expanding cancer treatment volumes and greater emphasis on managing treatment-related thrombotic risks are expected to strengthen adoption.

Application categories include

• Cardiovascular Disease (Dominating Segment)
• Oncology (Highest CAGR Segment)
• Dialysis
• Others

By Region

Heparin Market Share 2025, (Region)

North America

36%

South America

xx%

Europe

xx%

Middle East Africa

xx%

Asia Pacific

27%

North America held the largest position in the global Heparin Market in 2025, supported by a high prevalence of cardiovascular and thromboembolic diseases, well-established hospital procurement systems, advanced healthcare infrastructure, and the strong presence of major pharmaceutical manufacturers. The United States represents the region’s largest national market, driven by extensive cardiovascular procedures, sophisticated healthcare facilities, and established pharmaceutical manufacturing and distribution networks, while efforts to strengthen supply-chain resilience are encouraging greater interest in alternative heparin sourcing. Canada is witnessing steady demand growth, supported by an aging population, rising cardiovascular disease burden, and continued use of anticoagulant therapies across hospitals, surgical facilities, and other clinical settings.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by rising surgical and dialysis procedure volumes, expanding healthcare infrastructure, and the region’s strong position in heparin API manufacturing. China remains a major production and export hub, supported by vertically integrated API manufacturers and established supply networks serving domestic and international pharmaceutical markets. India is strengthening its position in generic low molecular weight heparin manufacturing, supported by a growing pharmaceutical industry, cost-competitive production capabilities, and expanding healthcare demand. Japan benefits from an aging population, advanced healthcare infrastructure, and high utilization of anticoagulant therapies in cardiovascular, surgical, and hospital settings. South Korea is supported by its technologically advanced pharmaceutical sector, increasing healthcare expenditure, and expanding capabilities in biopharmaceutical manufacturing and drug development. Collectively, these markets are contributing to regional growth through increasing demand for anticoagulation therapies, expanding pharmaceutical manufacturing capacity, and improvements in healthcare access.

Countries and Regions Covered

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• Germany (Largest Country Market)
• United Kingdom
• France
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The Heparin Market is consolidated, with competition spanning vertically integrated heparin API manufacturers, generic injectable suppliers, and branded pharmaceutical companies. Major participants include Baxter, B. Braun, Pfizer, Sanofi, Fresenius Kabi, Hikma Pharmaceuticals, and Aspen Pharmacare in finished-dose products, alongside specialized API and LMWH manufacturers such as Shenzhen Hepalink, Changzhou Qianhong Biopharma, Hebei Changshan Biochemical Pharmaceutical, Nanjing King-Friend Biochemical Pharmaceutical, Opocrin, and Bioibérica. Dr. Reddy’s Laboratories and Viatris participate primarily through broader injectable and generic pharmaceutical portfolios. Key competitive factors include vertical integration across heparin API and finished-dose manufacturing, reliable sourcing of porcine raw materials, stringent regulatory compliance, and global manufacturing capabilities. Leading companies are expanding heparin sodium and low molecular weight heparin production, increasing capacity for ready-to-administer and prefilled injectable formats, and broadening international regulatory approvals. Innovation is increasingly focused on alternative heparin sourcing, improved purification technologies, biosynthetic heparin, and advanced LMWH formulations, while manufacturers continue to strengthen supply-chain resilience and expand access across emerging markets.

Key Players

• Baxter International Inc. (US)
• B. Braun Melsungen AG (Germany)
• Pfizer Inc. (US)
• Sanofi S.A. (France)
• Fresenius Kabi AG (Germany)
• Dr. Reddy's Laboratories Ltd. (India)
• Viatris Inc. (US)
• Opocrin S.p.A. (Italy)
• Hikma Pharmaceuticals PLC (UK)
• Shenzhen Hepalink Pharmaceutical Co., Ltd. (China)
• Changzhou Qianhong Biopharma Co., Ltd. (China)
• Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
• Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (China)
• Bioibérica S.A.U. (Spain)
• Aspen Pharmacare Holdings Ltd. (South Africa)

Recent Market Developments

• July 2025: B. Braun Medical expanded its US heparin sodium injection portfolio with two new premixed products in 0.45% sodium chloride injection, strengthening its position as a leading provider of premixed heparin bags in the US market.
• August 2025: Fresenius Kabi Canada launched Heparin Sodium Injection USP 10,000 units/mL in a 0.5 mL vial, featuring a new 2D DataMatrix barcode. The launch expanded the company’s injectable heparin portfolio in Canada while improving product traceability, supporting Fresenius Kabi’s position in the hospital-focused heparin market.
• May 2026: Shenzhen Hepalink received approval in Kenya for its enoxaparin sodium injection (Clotex), expanding the product’s presence into another African market. The approval strengthens Hepalink’s international commercialization strategy and supports the growth of the low-molecular-weight heparin market in emerging regions.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is Heparin?

2

What is the CAGR of the Heparin Market?

3

Which product type leads the Heparin Market?

4

Which source segment dominates the Heparin Market?

5

Which route of administration has the highest market share?

6

What are the latest trends in the Heparin Market?

7

Who are the end users of heparin products?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates